Trial Profile
Efficacy and safety of Nivolumab in patients with relapsed or refractory Hodgkin Lymphoma: a real life, multicenter, retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 01 Nov 2020 Results published in the Annals of Hematology
- 01 Oct 2017 Results published in the Annals of Oncology.
- 24 Jul 2017 New trial record